Prior to founding Cuda Pharmaceuticals, Chris was the President of Global Pharmaceuticals, the generic division of Impax Laboratories, a NASDAQ listed specialty pharmaceutical company. Chris joined Impax in 2009 following a career at Barr Laboratories which culminated in the acquisition of the company by Teva in late 2008. Chris joined Barr in 1993 and held many and varied positions, culminating with his role as Executive Vice President, Global Strategic Planning. Breaking up his tenure at Barr, Chris worked at Pfizer as a project manager in the medical division from 1998 – 2002. Before joining Barr, Chris was at Sterling-Winthrop for two years and prior to that was engaged as an intern while attending pharmacy school with Pfizer and Lederle Laboratories.
Chris holds an MBA degree from Baruch College (CUNY), a pharmacy degree from St. John’s University and an engineering degree from The Johns Hopkins University and is also still a licensed and registered pharmacist in the State of New York.